<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596605</url>
  </required_header>
  <id_info>
    <org_study_id>LT2309-001</org_study_id>
    <nct_id>NCT04596605</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Tolerance Assessment of T2309</brief_title>
  <acronym>GATA</acronym>
  <official_title>Gastrointestinal Tolerance Assessment of T2309</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrointestinal Tolerance assessment of T2309 compared to a food supplement in 50 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Actual">March 4, 2021</completion_date>
  <primary_completion_date type="Actual">March 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Tolerance assessment</measure>
    <time_frame>12-week</time_frame>
    <description>Change from baseline in the mean of the daily composite score of gastrointestinal tolerance assessed with the Bristol Stool Scale (BSS) (composite score of stool frequency and consistency) and 10-point Likert scales filled (sum of the ratings of the 4 gastrointestinal symptoms scores) daily for 1 week prior to the completion of the 12-week treatment period (expressed in arbitrary unit/day (a.u./day), range 0-50)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite score of gastrointestinal tolerance</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from baseline in the mean of the daily composite score of gastrointestinal tolerance assessed with the BSS and 10-point Likert scales filled daily for 1 week prior to the completion of the 6-week treatment period (a.u./day, range 0-50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each component of the composite score of gastrointestinal tolerance</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>Change from baseline in the mean of each component of the composite score of gastrointestinal tolerance after 6 weeks and 12 weeks of treatment: 4 gastrointestinal symptoms (a.u./day, range 0-10), stool frequency (number of stools/day), stool consistency (a.u./stool, range 1-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>Assessed by a self-questionnaire to measure the global satisfaction (4-point scales)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>T2309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutrof Total</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsules daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>T2309</intervention_name>
    <description>Food for Special Medical Purpose / 4 capsules daily for 12 weeks</description>
    <arm_group_label>T2309</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrof Total</intervention_name>
    <description>2 capsules daily for 12 weeks</description>
    <arm_group_label>Nutrof Total</arm_group_label>
    <other_name>Food Supplement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated&#xD;
&#xD;
          -  Volunteer with no history of gastrointestinal disorders&#xD;
&#xD;
          -  Volunteer agreeing not to consume a food supplement other than IP during the study&#xD;
             period&#xD;
&#xD;
          -  Registered, or agreeing to be registered, in the National Registry of Healthy&#xD;
             Volunteers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known or suspected hypersensitivity or allergy&#xD;
&#xD;
          -  History of or active severe chronic disease or relevant systemic condition&#xD;
             incompatible with the study&#xD;
&#xD;
          -  Pregnancy or breast-feeding or have planned pregnancy in the next 4 months&#xD;
&#xD;
          -  Childbearing potential woman neither surgically sterilized nor using an adequate&#xD;
             contraception&#xD;
&#xD;
          -  Inability of the subject to understand the study procedures or to give informed&#xD;
             consent&#xD;
&#xD;
          -  Non-compliant subject&#xD;
&#xD;
          -  Participation in this study at the same time as another clinical investigation/study&#xD;
&#xD;
          -  Subject having received, during the last 12 months, indemnities for clinical trial&#xD;
             higher or equal to 4500 Euros&#xD;
&#xD;
          -  Subject being institutionalized because of legal or regulatory order, inmate of&#xD;
             psychiatric wards, prison or state institutions, or employee of the study site or of&#xD;
             the Sponsor's company&#xD;
&#xD;
          -  Subject not covered by the government health care scheme of the country in which&#xD;
             he/she is living&#xD;
&#xD;
          -  Subject with previous, current or anticipated prohibited treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Investigation Clinique</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

